FDA Advisory Committee Recommends Compounding Access for Six of Seven Reviewed Peptides
In an August 3 episode of its Public Health On Call podcast, the Johns Hopkins Bloomberg School of Public Health published an expert interview with Dr. Joshua Sharfstein, a former FDA Principal Deputy Commissioner, breaking down the outcome of the FDA's Pharmacy Compounding Advisory Committee meeting: the panel voted to recommend that six of the seven peptides under review be permitted for compounding, over the objection of the agency's own scientific staff, who cited insufficient safety and efficacy evidence. Sharfstein noted the panel's makeup had been criticized for financial conflicts of interest, and that the decision now returns to the FDA, which must determine whether and how to formally add the compounds to its permitted-compounding list — a process that could stretch into 2028 unless HHS invokes special authority to move faster.
This is a summary. The reporting is Johns Hopkins Bloomberg School of Public Health's, and the link below goes to the original article.
Read the full article at Johns Hopkins Bloomberg School of Public Health